Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Chardan Capital from $80.00 to $82.00.
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $58.00 to $65.00. They now have a "buy" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript [The Motley Fool]The Motley Fool
- Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2022 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter ResultsBusiness Wire
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter ResultsBusiness Wire
ARWR
Earnings
- 8/4/22 - Miss
ARWR
Sec Filings
- 8/4/22 - Form 10-Q
- 8/4/22 - Form 8-K
- 7/20/22 - Form 8-K
- ARWR's page on the SEC website